Halozyme Therapeutics (NASDAQ:HALO) COO Sells $277,904.97 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) COO Cortney Caudill sold 4,263 shares of the firm’s stock in a transaction dated Saturday, November 1st. The shares were sold at an average price of $65.19, for a total transaction of $277,904.97. Following the completion of the transaction, the chief operating officer directly owned 12,737 shares in the company, valued at $830,325.03. This represents a 25.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $67.35 on Monday. The stock has a 50 day moving average of $67.14 and a two-hundred day moving average of $65.06. Halozyme Therapeutics, Inc. has a 12 month low of $46.26 and a 12 month high of $79.50. The firm has a market cap of $7.92 billion, a P/E ratio of 14.18, a price-to-earnings-growth ratio of 0.36 and a beta of 0.95. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The firm had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. During the same period in the previous year, the company posted $1.27 earnings per share. The business’s revenue was up 22.1% on a year-over-year basis. On average, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Institutional Trading of Halozyme Therapeutics

Several institutional investors have recently made changes to their positions in the company. Campbell Newman Asset Management Inc. increased its stake in shares of Halozyme Therapeutics by 0.4% during the 3rd quarter. Campbell Newman Asset Management Inc. now owns 36,878 shares of the biopharmaceutical company’s stock valued at $2,705,000 after acquiring an additional 153 shares during the last quarter. Coldstream Capital Management Inc. grew its holdings in Halozyme Therapeutics by 1.9% in the third quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock valued at $654,000 after purchasing an additional 165 shares during the period. Alps Advisors Inc. increased its position in Halozyme Therapeutics by 3.0% during the third quarter. Alps Advisors Inc. now owns 5,926 shares of the biopharmaceutical company’s stock worth $435,000 after purchasing an additional 170 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in Halozyme Therapeutics by 6.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 174 shares during the period. Finally, Private Advisor Group LLC boosted its holdings in shares of Halozyme Therapeutics by 0.8% in the 3rd quarter. Private Advisor Group LLC now owns 23,623 shares of the biopharmaceutical company’s stock valued at $1,733,000 after purchasing an additional 184 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on HALO. Citizens Jmp increased their target price on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research report on Tuesday, November 4th. Zacks Research downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Morgan Stanley decreased their target price on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research note on Monday, October 20th. Weiss Ratings restated a “hold (c+)” rating on shares of Halozyme Therapeutics in a report on Monday, December 15th. Finally, The Goldman Sachs Group restated a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $75.10.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.